{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:46Z","timestamp":1785132106429,"version":"3.55.0"},"reference-count":178,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>T cell-directed immunotherapies have transformed the treatment of hematological malignancies, but durable benefit remains limited by relapse, poor persistence, incomplete immune reconstitution and infection. These outcomes depend not only on target-antigen expression but also on the functional quality of the T cell compartment. In this Review, we define T cell fitness as a multidimensional capacity that includes cellular availability, memory reserve, proliferative competence, cytotoxic function, metabolic resilience, resistance to chronic stimulation and persistence. We distinguish exhaustion, senescence and terminal differentiation as overlapping but non-equivalent states and propose a measurable, modality-specific assessment framework rather than reliance on a single marker. We then compare how these states arise in multiple myeloma, lymphoma, acute lymphoblastic leukemia and acute myeloid leukemia, emphasizing the effects of age, tissue niche, disease burden and prior therapy. We critically appraise evidence from CAR-T cell therapy, bispecific antibodies and checkpoint blockade, including the limitations of predominantly retrospective, correlative and disease-specific datasets. Finally, we translate the fitness framework into clinical questions: when to collect cells, how to select bridging therapy, which biomarkers merit prospective testing, how treatment duration and sequencing may preserve immune competence, and where gene-edited products, CAR-NK cells and metabolic interventions may reduce dependence on compromised autologous T cells. A fitness-based approach may support more precise biomarker development and safer treatment selection, but prospective validation and modality-specific thresholds are still required.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1895434","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:50Z","timestamp":1785130850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoshuang","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Medical Research Center for Blood Diseases","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Su","sequence":"additional","affiliation":[{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxue","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Medical Research Center for Blood Diseases","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxi","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Medical Research Center for Blood Diseases","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Huang","sequence":"additional","affiliation":[{"name":"Wuwei People\u2019s Hospital Wuwei","place":["Wuwei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gansu Province Clinical Medical Research Center for Blood Diseases","place":["Lanzhou, China"]},{"name":"Department of Hematology, The Second Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[{"name":"Gansu Province Clinical Medical Research Center for Blood Diseases","place":["Lanzhou, China"]},{"name":"Department of Hematology, The Second Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"CAR-T cells and T cell therapies for cancer: A translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2024.2445145","article-title":"Practical insights into bispecific antibody therapy in multiple myeloma","volume":"24","author":"Kawasaki","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1424925","article-title":"Bispecific antibody targets and therapies in multiple myeloma","volume":"15","author":"Rees","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419","article-title":"CAR-T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a bispecific B-cell and T cell engaging antibody, in the treatment of B-cell Malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2275457","article-title":"Building safety into CAR-T therapy","volume":"19","author":"Peters","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: Dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0202","article-title":"Recent advances in immune-based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T cell phenotypes associated with effective CAR-T cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1070353","article-title":"Innovation in BCMA CAR-T therapy: Building beyond the Model T","volume":"12","author":"Banerjee","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: Advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.20944\/preprints202410.0776.v1","article-title":"Real-world evidence evaluating teclistamab in patients with relapsed\/refractory multiple myeloma: A systematic literature review","volume":"17","author":"Derman","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241282115","article-title":"B-cell maturation antigen-directed immunotherapies for the treatment of relapsed\/refractory multiple myeloma: A review of the literature and implications for clinical practice","volume":"59","author":"Peery","year":"2025","journal-title":"Ann Pharmacother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2016.03.001","article-title":"CAR-T cell therapies from the transfusion medicine perspective","volume":"30","author":"Fesnak","year":"2016","journal-title":"Transfus Med Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: Pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","article-title":"Checkpoint inhibitors in hematological Malignancies","volume":"10","author":"Ok","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B29","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"113","author":"Hughes","year":"2026","journal-title":"Am Fam Physician"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026313","article-title":"Evolution of multiple myeloma from a genomic perspective","volume":"147","author":"Maura","year":"2026","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0001","article-title":"Multiple myeloma, version 5.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Kumar","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"B32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-026-01461-7","article-title":"Toward a cure for multiple myeloma within a decade","volume":"16","author":"Mohty","year":"2026","journal-title":"Blood Cancer J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1038\/s41467-023-41562-6","article-title":"Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance","volume":"14","author":"Botta","year":"2023","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00755-x","article-title":"New horizons in our understanding of precursor multiple myeloma and early interception","volume":"24","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/17474086.2024.2370552","article-title":"T cell exhaustion in multiple myeloma","volume":"17","author":"Zylka","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021221","article-title":"CAR-T cell therapy in multiple myeloma: Mission accomplished","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: Current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion'","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological Malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13642","article-title":"T cell exhaustion in CAR-T cell therapy and strategies to overcome it","volume":"169","author":"Yin","year":"2023","journal-title":"Immunology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological Malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040598","article-title":"T cell dysfunction as a limitation of adoptive immunotherapy: Current concepts and mitigation strategies","volume":"13","author":"Janelle","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101031","DOI":"10.1016\/j.medj.2026.101031","article-title":"T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic Malignancies: Mechanisms and implications","volume":"7","author":"Muth","year":"2026","journal-title":"Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8(+) T cell exhaustion","volume":"26","author":"Sun","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202520634","article-title":"T cell exhaustion in cancer immunotherapy: Heterogeneity, mechanisms, and therapeutic opportunities","volume":"13","author":"Yu","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201099","article-title":"CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions","volume":"34","author":"Zhao","year":"2026","journal-title":"Mol Ther Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02327-3","article-title":"Revitalizing T cells: Breakthroughs and challenges in overcoming T cell exhaustion","volume":"11","author":"Wu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2026.03.002","article-title":"Epigenetic, epitranscriptomic, and metabolic control of T cell exhaustion","author":"Slater","year":"2026","journal-title":"Trends Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-026-01405-y","article-title":"T cell adaptation in chronic infections and tumors","volume":"23","author":"Luxenburger","year":"2026","journal-title":"Cell Mol Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1476904","DOI":"10.3389\/fimmu.2024.1476904","article-title":"CD8(+) T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: Key to the success of immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156081","article-title":"T cell exhaustion: Focus on molecular pathways","volume":"272","author":"Dang","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01161-6","article-title":"The diversity of CD8(+) T cell dysfunction in cancer and viral infection","volume":"25","author":"Galluzzi","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41568-025-00883-y","article-title":"Epigenetic regulation of T cell exhaustion in cancer","volume":"26","author":"Kang","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctt1hfr0s3.44","article-title":"Metabolic and epigenetic regulation of T cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1700039","article-title":"Epigenetic regulation of CD8(+) T cell exhaustion: Recent advances and update","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2024.07.001","article-title":"T cell exhaustion and senescence for ovarian cancer immunotherapy","author":"Zhao","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1338680","article-title":"T cell senescence: A new perspective on immunotherapy in lung cancer","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0180-1","article-title":"Mechanisms underlying T cell ageing","volume":"19","author":"Goronzy","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15770","article-title":"Hallmarks of the aging T cell system","volume":"288","author":"Zhang","year":"2021","journal-title":"FEBS J"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009462","article-title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","volume":"12","author":"Ullrich","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.semcancer.2024.11.003","article-title":"Decoding T cell senescence in cancer: Is revisiting required","volume":"108","author":"Magkouta","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nri890","article-title":"Telomeres in T and B cells","volume":"2","author":"Hodes","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: Molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063374","article-title":"CD8(+) T cell senescence: Lights and shadows in viral infections, autoimmune disorders and cancer","volume":"23","author":"Tedeschi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nri2959","article-title":"Are senescence and exhaustion intertwined or unrelated processes that compromise immunity","volume":"11","author":"Akbar","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-025-01735-w","article-title":"Immunosenescence and cancer: Molecular hallmarks, tumor microenvironment remodeling, and age-specific immunotherapy challenges","volume":"18","author":"Liu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41420-025-02468-y","article-title":"Metabolic reprogramming in T cell senescence: A novel strategy for cancer immunotherapy","volume":"11","author":"Liu","year":"2025","journal-title":"Cell Death Discov"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB co-stimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"101586","DOI":"10.1016\/j.omtm.2025.101586","article-title":"CAR-T cell engineering impacts antigen-independent activation and co-inhibition","volume":"33","author":"Schultheiss","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149150","article-title":"CD8+ T cell differentiation and dysfunction inform treatment response in acute myeloid leukemia","volume":"144","author":"Mazziotta","year":"2024","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.3.311","article-title":"CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity","volume":"10","author":"Mollet","year":"1998","journal-title":"Int Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41577-025-01238-2","article-title":"Guidelines for T cell nomenclature","volume":"26","author":"Masopust","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16359","article-title":"CX3CR1(+)CD8(+) T cells: Key players in antitumor immunity","volume":"115","author":"Ma","year":"2024","journal-title":"Cancer Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.06.025","article-title":"Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation","volume":"56","author":"Zwijnenburg","year":"2023","journal-title":"Immunity"},{"key":"B87","doi-asserted-by":"publisher","first-page":"116614","DOI":"10.1016\/j.intimp.2026.116614","article-title":"CD8(+) T(EMRA) cells: A double-edged sword in immunity and disease-mechanisms and therapeutic targets","volume":"179","author":"Ma","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101992","article-title":"Deciphering immune predictors of immunotherapy response: A multiomics approach at the pan-cancer level","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-021-01201-8","article-title":"High-throughput and single-cell T cell receptor sequencing technologies","volume":"18","author":"Pai","year":"2021","journal-title":"Nat Methods"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03809-w","article-title":"CAR-T cell therapy in AML: Recent progress and future perspectives","volume":"120","author":"Saito","year":"2024","journal-title":"Int J Hematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275329","article-title":"Impacting T cell fitness in multiple myeloma: Potential roles for selinexor and XPO1 inhibitors","volume":"14","author":"Binder","year":"2023","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414264","article-title":"Advances in CAR-NK cell therapy for hematological Malignancies","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B95","doi-asserted-by":"publisher","first-page":"780442","DOI":"10.4018\/979-8-3373-2096-0.ch006","article-title":"T cell fitness and autologous CAR-T cell therapy in haematologic Malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic Malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1684\/hma.2021.1638","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01653-7","article-title":"Immune senescence in multiple myeloma-a role for mitochondrial dysfunction","volume":"36","author":"Seymour","year":"2022","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241245194","article-title":"Treatment of multiple myeloma: What is the impact on T cell function","volume":"15","author":"Li","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2147\/itt.s534784","article-title":"T cells dysfunction in multiple myeloma","volume":"14","author":"Cai","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1038\/s41467-026-68718-4","article-title":"Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma","volume":"17","author":"Foster","year":"2026","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.12.007","article-title":"Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas","volume":"12","author":"Tao","year":"2026","journal-title":"Trends Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10555-024-10228-0","article-title":"CAR-T cell therapy for B-cell lymphomas: outcomes and resistance mechanisms","volume":"44","author":"Kearl","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR-T cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01687-x","article-title":"Deconvolution of clinical variance in CAR-T cell pharmacology and response","volume":"41","author":"Kirouac","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR-T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14109","article-title":"Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia","volume":"112","author":"Agrawal","year":"2024","journal-title":"Eur J Haematol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR-T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19508","article-title":"The Menin story in acute myeloid leukaemia-the road to success","volume":"205","author":"Kuhn","year":"2024","journal-title":"Br J Haematol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2018.05.044","article-title":"Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications","volume":"151","author":"Infante","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02096-9","article-title":"The rewired immune microenvironment in leukemia","volume":"26","author":"Ciantra","year":"2025","journal-title":"Nat Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01003-x","article-title":"Bone marrow inflammation in haematological Malignancies","volume":"24","author":"de Jong","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40164-025-00726-4","article-title":"Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting","volume":"14","author":"Ocana-Cara","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","article-title":"Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy","volume":"40","author":"Dabas","year":"2023","journal-title":"Med Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6328","article-title":"CAR-T cell therapy in large B cell lymphoma","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1140541","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2147919","article-title":"Radiation therapy prior to CAR-T cell therapy in lymphoma: impact on patient outcomes","volume":"15","author":"Figura","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010709","article-title":"Prior chemotherapy deteriorates T cell quality for CAR-T cell therapy in B-cell non-Hodgkin's lymphoma","volume":"13","author":"Herzberg","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433774","article-title":"Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy","volume":"15","author":"Fu","year":"2024","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1152498","DOI":"10.1182\/blood-2022-163106","article-title":"Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell Malignancies","volume":"14","author":"Garcia-Calderon","year":"2023","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR-T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285343","article-title":"New bispecific antibodies in diffuse large B-cell lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3333","article-title":"T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41408-024-01114-7","article-title":"Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma","volume":"14","author":"Chakraborty","year":"2024","journal-title":"Blood Cancer J"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1177\/25151355241288453","article-title":"Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy","volume":"12","author":"Kamali","year":"2024","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B147","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","article-title":"Immune checkpoint inhibitors for multiple myeloma immunotherapy","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options","volume":"30","author":"Le Calvez","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for the treatment of triple-class-exposed, relapsed or refractory multiple myeloma","volume":"31","author":"Sharma","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00320-x","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1764549","article-title":"Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aec2632","article-title":"IL-7\/IL-15\/IL-21 cytokine-fusion scaffold generates highly functional CAR-T cells enriched in long-lived T memory stem cells","volume":"12","author":"Cole","year":"2026","journal-title":"Sci Adv"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-21-0110","article-title":"Mitochondria as playmakers of CAR-T cell fate and longevity","volume":"9","author":"Rostamian","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"B159","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/btt.s291768","article-title":"Armored CAR-T cells: The next chapter in T cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biologics"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR-T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1535869","article-title":"Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia","volume":"14","author":"Ho","year":"2024","journal-title":"Front Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"298","DOI":"10.21037\/atm-22-20","article-title":"Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory\/relapsed diffuse large B-cell lymphoma","volume":"10","author":"Ping","year":"2022","journal-title":"Ann Transl Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR-T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168996","article-title":"CAR-T cell therapy in hematological Malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR-T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8765028","article-title":"Chimeric antigen receptor T cell exhaustion during treatment for hematological Malignancies","volume":"2020","author":"Shen","year":"2020","journal-title":"BioMed Res Int"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat Cancer"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008854","article-title":"Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia","volume":"7","author":"Irani","year":"2023","journal-title":"Blood Adv"},{"key":"B172","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41571-023-00749-y","article-title":"CAR-T cells show superiority over standard therapies for RRMM","volume":"20","author":"Killock","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1038\/s41467-021-23324-4","article-title":"Interpretation of T cell states from single-cell transcriptomics data using reference atlases","volume":"12","author":"Andreatta","year":"2021","journal-title":"Nat Commun"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000613","article-title":"Single-cell sequencing in hematology","volume":"32","author":"Brierley","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70117","article-title":"Antigen escape in CAR-T therapy: A tumor microenvironment perspective from hematological to solid tumors","volume":"158","author":"Wang","year":"2026","journal-title":"Int J Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105281","article-title":"Rewiring immunity: CAR-T cells as a paradigm shift in hematologic oncology","volume":"222","author":"Janes","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s43556-025-00401-4","article-title":"CAR-engineered cell therapies: current understandings and future perspectives","volume":"7","author":"Bayat","year":"2026","journal-title":"Mol BioMed"},{"key":"B178","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00277-026-06919-z","article-title":"Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy","volume":"105","author":"Al-Khreisat","year":"2026","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:52Z","timestamp":1785130852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":178,"alternative-id":["10.3389\/fimmu.2026.1895434"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1895434","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1895434"}}